DE69918089D1 - Btk inhibitoren und verfahren zur identifizierung und verwendung - Google Patents

Btk inhibitoren und verfahren zur identifizierung und verwendung

Info

Publication number
DE69918089D1
DE69918089D1 DE69918089T DE69918089T DE69918089D1 DE 69918089 D1 DE69918089 D1 DE 69918089D1 DE 69918089 T DE69918089 T DE 69918089T DE 69918089 T DE69918089 T DE 69918089T DE 69918089 D1 DE69918089 D1 DE 69918089D1
Authority
DE
Germany
Prior art keywords
identification
btk inhibitors
inhibitors
btk
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69918089T
Other languages
English (en)
Other versions
DE69918089T2 (de
Inventor
Fatih M Uckun
Yaguo Zheng
Sutapa Ghosh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parker Hughes Institute
Original Assignee
Parker Hughes Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/273,191 external-priority patent/US6303652B1/en
Application filed by Parker Hughes Institute filed Critical Parker Hughes Institute
Application granted granted Critical
Publication of DE69918089D1 publication Critical patent/DE69918089D1/de
Publication of DE69918089T2 publication Critical patent/DE69918089T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/40—Y being a hydrogen or a carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69918089T 1998-04-17 1999-04-19 Btk inhibitoren und verfahren zur identifizierung und verwendung Expired - Fee Related DE69918089T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8209498P 1998-04-17 1998-04-17
US82094P 1998-04-17
US273191 1999-03-19
US09/273,191 US6303652B1 (en) 1998-08-21 1999-03-19 BTK inhibitors and methods for their identification and use
PCT/US1999/008556 WO1999054286A2 (en) 1998-04-17 1999-04-19 Btk inhibitors and methods for their identification and use

Publications (2)

Publication Number Publication Date
DE69918089D1 true DE69918089D1 (de) 2004-07-22
DE69918089T2 DE69918089T2 (de) 2005-07-14

Family

ID=26767041

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69918089T Expired - Fee Related DE69918089T2 (de) 1998-04-17 1999-04-19 Btk inhibitoren und verfahren zur identifizierung und verwendung

Country Status (13)

Country Link
EP (1) EP1071658B1 (de)
JP (1) JP2002512216A (de)
KR (1) KR20010042804A (de)
AT (1) ATE269295T1 (de)
AU (1) AU3653099A (de)
CA (1) CA2328962A1 (de)
DE (1) DE69918089T2 (de)
ES (1) ES2222705T3 (de)
HU (1) HUP0102661A2 (de)
IL (1) IL139080A0 (de)
MX (1) MXPA00010150A (de)
NO (1) NO20005224L (de)
WO (1) WO1999054286A2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6306897B1 (en) * 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
EP1230232B1 (de) 1999-11-05 2004-02-25 Cytovia, Inc. Substituierte 4h-chromene und ähnliche verbindungen als kaspasis aktivatoren und apoptosis induktoren und deren verwendung
US6589992B2 (en) 1999-11-30 2003-07-08 Parker Hughes Institute Inhibiting collagen-induced platelet aggregation
CA2390857A1 (en) * 1999-11-30 2001-06-14 Fatih M. Uckun Inhibitors of collagen-induced platelet aggregation
GB0005345D0 (en) * 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
AU2001236361A1 (en) * 2000-10-20 2002-05-06 Parker Hughes Institute Treatment of asthma with lfm analogues
JP2004533209A (ja) * 2000-10-23 2004-11-04 ブリストル−マイヤーズ　スクイブ　カンパニー ブルトンチロシンキナーゼおよびブルトンチロシンキナーゼ媒体のモデュレーターおよびその同定方法および骨粗鬆症および関連疾患状態の治療および予防におけるその使用
DE60221104T2 (de) * 2001-03-07 2008-03-13 TELIK, INC., Palo Alto Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
DE10112924A1 (de) * 2001-03-13 2002-10-02 Erich Eigenbrodt 1-Butansäurederivate, pharmazeutische Zusammensetzungen enthaltend solche Derivate und Verwendungen solcher Derivate
CA2441088A1 (en) * 2001-03-13 2002-09-19 Protagen Ag 1-butyric acid derivatives such as carbomethoxypropionyl cyanide or leflunomide derivatives, and the therapeutic use thereof
US6858607B1 (en) 2001-05-16 2005-02-22 Cytovia, Inc. 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
CA2447010C (en) 2001-05-16 2011-08-02 Cytovia, Inc. Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2002092076A1 (en) * 2001-05-16 2002-11-21 Cytovia, Inc. Substituted coumarins and quinolines as caspases activators
WO2003027320A2 (en) * 2001-09-24 2003-04-03 University Of Aarhus Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1
WO2003096982A2 (en) 2002-05-16 2003-11-27 Cytovia, Inc. Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
CA2484702A1 (en) 2002-05-16 2003-11-27 Cytovia, Inc. Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2004024676A1 (de) * 2002-09-06 2004-03-25 Schebo®Biotech Ag Verbindungen zur modulation des glykolyse-enzym-und/oder transaminase-komplexes
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
EP1804782A1 (de) * 2004-10-19 2007-07-11 Aventis Pharmaceuticals Inc. Verwendung von (z)-2-cyano-3-hydroxy-but-2-ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung entzündlicher darmerkrankungen
WO2008033858A2 (en) * 2006-09-11 2008-03-20 Cgi Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
EP2526934B1 (de) 2006-09-22 2015-12-09 Pharmacyclics LLC Hemmer der Bruton-Tyrosinkinase
EP2546651A1 (de) * 2007-03-14 2013-01-16 Bionsil S.r.l. Modulatorverbindungen der Arzneimittelresistenz in Epitheltumorzellen
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CA2701275C (en) * 2007-10-23 2016-06-21 F. Hoffmann-La Roche Ag Kinase inhibitors
WO2009060835A1 (ja) * 2007-11-05 2009-05-14 Kyoto University 新規ユビキリン結合性小分子
US8389757B2 (en) 2008-06-05 2013-03-05 Alembic Ltd. Process for preparing teriflunomide
ES2660418T3 (es) 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
MX388981B (es) 2010-04-05 2025-03-20 Fosun Orinove Pharmatech Inc Inhibidores de enzima 1 dependiente de inositol (ire-1alfa).
CA3240281A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
JP2014520863A (ja) 2011-07-13 2014-08-25 ファーマサイクリックス，インク． Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
WO2013148603A1 (en) 2012-03-27 2013-10-03 Takeda Pharmaceutical Company Limited Cinnoline derivatives as as btk inhibitors
NZ713828A (en) 2012-06-04 2017-05-26 Pharmacyclics Llc Crystalline forms of a bruton’s tyrosine kinase inhibitor
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
CA2890934A1 (en) 2012-11-15 2014-05-22 Pharmacyclics, Inc. Pyrrolopyrimidine compounds as kinase inhibitors
US10876096B2 (en) 2012-11-28 2020-12-29 Corning Incorporated Cell culture medium for enhanced hepatocyte function
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
KR101737723B1 (ko) 2013-04-02 2017-05-18 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
CA2919996A1 (en) 2013-08-02 2015-02-05 Pharmacyclics Llc Methods for the treatment of solid tumors
EP2832358A1 (de) * 2013-08-02 2015-02-04 Bionsil S.r.l. Pharmazeutisches Kit zur Verwendung bei der Behandlung von Darm- und kolorektalem Krebs
US9415050B2 (en) 2013-08-12 2016-08-16 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
PE20160560A1 (es) 2013-09-30 2016-06-09 Pharmacyclics Llc DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDIN COMO INHIBIDORES IRREVERSIBLES DE LA TIROSINA CINASA DE BRUTON (BTK)
WO2015089481A2 (en) 2013-12-13 2015-06-18 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
JP6879740B2 (ja) 2013-12-13 2021-06-02 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
CN105272882B (zh) * 2014-07-23 2019-05-31 欣凯医药化工中间体（上海）有限公司 一种环保简便制备泰瑞米特的方法
AU2015296215A1 (en) 2014-08-01 2017-03-23 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
RU2017106795A (ru) 2014-08-07 2018-09-07 Фармасайкликс Элэлси Новые составы ингибитора тирозинкиназы брутона
EP3715346B1 (de) 2014-10-22 2024-01-03 Dana-Farber Cancer Institute, Inc. Thiazolylhaltige verbindungen zur behandlung proliferativer erkrankungen
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
JP7305352B2 (ja) 2016-03-31 2023-07-10 武田薬品工業株式会社 イソキノリニルトリアゾロン錯体
WO2018111902A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
EP3942045A1 (de) 2019-03-21 2022-01-26 Onxeo Dbait-molekül in kombination mit einem kinaseinhibitor zur behandlung von krebs
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2555685A1 (de) * 1975-12-11 1977-06-23 Hoechst Ag Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
EP0527736B1 (de) * 1990-05-18 1997-04-16 Hoechst Aktiengesellschaft Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
CA2080554A1 (en) * 1991-10-15 1993-04-16 Mitsubishi Chemical Corporation Styrene derivatives
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
EP0674643A1 (de) * 1992-12-23 1995-10-04 Smithkline Beecham Corporation Cumarin-derivate als retrovirale inhibitoren
GB9322781D0 (en) * 1993-11-04 1993-12-22 Roussel Lab Ltd Aromatic amides
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5489697A (en) * 1994-08-03 1996-02-06 Medichem Research, Inc. Method for the preparation of (+)-calanolide A and intermediates thereof
US5608085A (en) * 1995-02-27 1997-03-04 The University Of Tennessee Research Corporation Synthesis of optically active calanolides A and B and enantiomers and related compounds
WO1996031206A2 (en) * 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
IT1289238B1 (it) * 1996-12-10 1998-09-29 Bio S S P A Ora Bio S S R L Composizioni farmaceutiche per il trattamento di infezioni virali comprendenti una 4 arilcumarina

Also Published As

Publication number Publication date
EP1071658A2 (de) 2001-01-31
HUP0102661A2 (hu) 2001-11-28
WO1999054286A3 (en) 2000-05-04
IL139080A0 (en) 2001-11-25
MXPA00010150A (es) 2002-05-14
JP2002512216A (ja) 2002-04-23
NO20005224D0 (no) 2000-10-17
AU3653099A (en) 1999-11-08
NO20005224L (no) 2000-12-18
KR20010042804A (ko) 2001-05-25
ATE269295T1 (de) 2004-07-15
DE69918089T2 (de) 2005-07-14
CA2328962A1 (en) 1999-10-28
ES2222705T3 (es) 2005-02-01
EP1071658B1 (de) 2004-06-16
WO1999054286A2 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
DE69918089D1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
DE60007095D1 (de) Calanolide zur hemmung von btk
DE60125715D1 (de) Verfahren und testsysteme zur identifizierung von elite event gat-zm1 in biologischen proben
DE60214946D1 (de) Verfahren und System zur Bereitstellung von Informationen
ATE471374T1 (de) Immunomodulatorische polynukleotide und verfahren zur deren verwendung
ATE467301T1 (de) Verfahren und vorrichtung für gleichrangigen diensten
ATE520466T1 (de) Apparat und verfahren zur modifizierung von magnetisch inmmobilizierte biomolekulen
EP1254267A4 (de) Zusammensetzungen und methoden zur früherkennung von eierstockkrebs
DE60018907D1 (de) Verfahren und zusammensetzung zur zementierung von bohrlöchern
ATE547101T1 (de) Verfahren zur verwendung von diketopiperazinen und zusammensetzungen, die diese enthalten
DE60038328D1 (de) Gerät, Verfahren und Medium zur Informationsverarbeitung
DE602004018714D1 (de) Verfahren zur Bereitstellung von zweiteiligen, selbstklebenden Dentalmassen
ATE458191T1 (de) Verfahren zur selektion von partikeln
DE60309647D1 (de) System und Verfahren zur gesicherten Behandlung von Kontrollinformationen
DE60210265D1 (de) Verfahren und zwischenprodukte zur herstellung von 4-aminochinolin-cetp-inhibitoren
EA200001129A2 (ru) Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина
ATA1112001A (de) Verfahren zur tragekontrolle von regulierungen
DE50203510D1 (de) Verfahren zur erkennung und identifizierung von objekten
DE60021960D1 (de) Verfahren zur Kompensation von Neigung und/oder Defokussierung, und Vorrichtung für dasselbige
DE69925482D1 (de) Verfahren, einrichtung und gerät zur authentifizierung
DE60023461D1 (de) Verdichter und verfahren zur schmierung des kompressors
DE60315575D1 (de) Verfahren und Vorrichtung zur Untersuchung von Oberflächen
DE60029039D1 (de) Verfahren, Vorrichtung und Computerprogramm zur Verschlüsselung von Computertelefonie
DE60136607D1 (de) System und Verfahren zur Lieferung von Karteninformationen
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee